Japan approves Ozempic for type 2 diabetes

Japan's Ministry of Health, Labour and Welfare and its drug reviewer, the Pharmaceuticals and Medical Devices Agency (PMDA), approved Ozempic Subcutaneous Injection 2 mg for type 2 diabetes mellitus in March 2018 ^[1]. Rybelsus 3 mg tablets, an oral version of the same active ingredient, followed in June 2020 ^[1]. Both products contain semaglutide, a glucagon-like peptide-1 (GLP-1) analog ^[1].

This history comes from a PMDA review report dated December 27, 2022, and a related deliberation report dated February 6, 2023, which were prepared as Japan considered a separate application from Novo Nordisk Pharma Ltd. for Wegovy, a higher-dose semaglutide injection aimed at obesity rather than diabetes ^[1]. The documents note that Wegovy "contains the same active ingredient" as the earlier-approved Ozempic and Rybelsus products ^[1].

According to the same PMDA review, non-clinical pharmacology data submitted for the original Ozempic approval showed that semaglutide lowers body weight in animal studies and suggested this effect may be tied mainly to actions on the hypothalamus, the brain region involved in appetite regulation ^[1]. That earlier pharmacology work, cited from a November 16, 2017 Ozempic review report, became part of the scientific foundation later used to support Wegovy's obesity indication in Japan ^[1].

Novo Nordisk applied for Wegovy's approval in Japan on August 25, 2021 ^[1]. PMDA's review concluded the product had efficacy for obesity disease and an acceptable safety profile given its benefits, and Japan's First Committee on New Drugs reached the same conclusion at a meeting on January 27, 2023 ^[1]. By comparison, Wegovy had already been approved in the United States in June 2021 and in the European Union in January 2022, and by June 2022 it had been cleared in six countries or regions ^[1].

Why it matters for patients

For patients in the United States, this history mostly matters as context rather than as something that changes access today. Ozempic and Rybelsus have been available to treat type 2 diabetes in the U.S. for years, and Wegovy is approved here for weight management. The Japanese timeline shows that regulators in different countries do not always move at the same pace or for the same indication first — Japan approved semaglutide for diabetes in 2018 but did not clear the obesity-focused Wegovy version until the 2022–2023 review process described in these documents, well after the U.S. approval in 2021 ^[1].

The pharmacology details in the review also help explain, in general terms, why semaglutide can lead to weight loss: the drug appears to reach appetite-related regions of the brain, based on animal studies described in the filing ^[1]. That is background science, not new clinical guidance, and it does not change how the drug is used by patients already taking it.

What happens next

The sources here are regulatory review documents from PMDA, not current news, so no future dated milestones are described. It is not known from these sources whether Japan's Wegovy approval process led to any changes in prescribing rules, cost, or availability for U.S. patients, since the review materials focus specifically on Japan's domestic regulatory history and comparisons to approval dates in the U.S. and EU ^[1].